In vitro and in vivo anti-tumor activities of anti-EGFR single-chain variable fragment fused with recombinant gelonin toxin

Treatment of Hematologic Malignancies with Immunotoxins and Antibody-Drug Conjugates

(2011) D. J. FitzGerald et al.   CANCER RESEARCH

Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties

(2010) Christopher M. Pirie et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Phase II Study of Paclitaxel, Carboplatin, and Cetuximab as First Line Treatment, for Patients with Advanced Non-small Cell Lung Cancer (NSCLC): Results of OPN-017

(2010) Hossein Borghaei et al.   Journal of Thoracic Oncology

T cell-engaging BiTE antibodies specific for EGFR potently eliminate KRAS- and BRAF-mutated colorectal cancer cells

(2010) Ralf Lutterbuese et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Construction and Characterization of Novel, Recombinant Immunotoxins Targeting the Her2/neu Oncogene Product: In vitro and In vivo Studies

(2009) Y. Cao et al.   CANCER RESEARCH

Activity of panitumumab alone or with chemotherapy in non-small cell lung carcinoma cell lines expressing mutant epidermal growth factor receptor

(2009) D. J. Freeman et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor activity of fibroblast growth factor receptor 3-specific immunotoxins in a xenograft mouse model of bladder carcinoma is mediated by apoptosis

(2008) J. L. Martinez-Torrecuadrada et al.   MOLECULAR CANCER THERAPEUTICS